Why the study?
The efficacy of antithrombotic treatment strategies in CABG patients with indications for long-term anticoagulation has not been compared in large prospective trials, and guidelines do not specify the optimal choice. Adding antiplatelets to chronic anticoagulation after CABG is common but may increase bleeding risk.
Does combined antiplatelet and anticoagulant therapy reduce major adverse cardiac events without increasing major bleeding compared to anticoagulant monotherapy in patients requiring anticoagulation after CABG?
Does combined antiplatelet and anticoagulant therapy reduce major adverse cardiac events without increasing major bleeding compared to anticoagulant monotherapy in patients requiring anticoagulation after CABG?
In real-world patients requiring anticoagulation after CABG, adding antiplatelet therapy (ASA or P2Y12 inhibitors) to anticoagulants did not reduce 1-year MACE compared to anticoagulant monotherapy, while combining anticoagulants with oral P2Y12 inhibitors more than doubled the risk of major bleeding.
Answers are grounded in this paper and cite their sources.
No MACE difference was associated with added antiplatelets after CABG; leaves open net benefit of combination therapy pending randomized data.
Introduction A growing number of patients undergoing coronary artery bypass grafting (CABG) have indications for long-term anticoagulation. The efficacy of strategies of antithrombotic treatment in this population has not been compared in large prospective trials, and current guidelines do not specify the optimal treatment choice. While addition of antiplatelets to chronic anticoagulation after CABG is common, it may increase the risk of bleeding complications. Purpose The aim of the study was to compare post-CABG antithrombotic treatment strategies in terms of efficacy and safety in one-year post-CABG observation in patients undergoing CABG with indications for long-term anticoagulation, based on the real-world data. Methods Real-world data extracted from the THIN database was analysed. Adult patients from France and Great Britain undergoing CABG between 2010 and 2022, treated with anticoagulants within a year after the CABG and followed up at least for a year after CABG or until death were included. The outcomes were compared between patients treated with anticoagulants (VKA or NOAC) in monotherapy (AC), anticoagulants in combination with ASA (AC+ASA), or anticoagulants with oral P2Y12 inhibitor (AC+P2Y12i), with or without ASA. The efficacy was assessed in terms of the occurrence of major adverse cardiac events (MACE), and the safety in terms of occurrence of major bleeding. Inverse probability of treatment weights from propensity score model including age, sex, history of hypertension, atrial fibrillation, kidney disease, and diabetes mellitus were used to fit a weighted Cox model, to evaluate effects on balanced groups. Results Among 962 patients included in the analysis, 326 (33.9%) patients were on AC; 547 (56.9%) were on AC+ASA; 89 (9.2%) were on AC+P2Y12i therapies. The mean age was 74.2(±9.4) years, the majority were men (86.9%). In one-year post-CABG observation, the MACE occurred in 7.4% and major bleeding occurred in 4.0% of patients. In the analysis performed using weighted Cox model, no significant effect of type of antithrombotic treatment strategy on risk of MACE was observed: AC+ASA vs. AC HR 1.12 (95%CI 0.82-1.53); AC+P2Y12i vs. AC 1.09 (0.67-1.77). For safety outcomes, significant increase in risk of major bleeding was observed in AC+P2Y12i in comparison to AC, while in AC+ASA the effect was not statistically significant: AC+ASA vs. AC HR 1.21 (95%CI 0.75-1.94); AC+P2Y12i vs. AC 2.34 (1.20-4.56). Conclusions The efficacy of the antithrombotic treatment strategy measured in terms of risk of MACE was comparable among patients treated with anticoagulants in monotherapy, anticoagulants in combination with ASA, or anticoagulants combined with oral P2Y12 inhibitors. In contrast, in the population balanced for baseline characteristics, risk of major bleeding was significantly higher in group treated with anticoagulants with oral P2Y12 inhibitors in comparison to group receiving anticoagulant monotherapy.
No takes yet. Share an insight, caveat, or question.
Segiet et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: